Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Irinotecan and Docetaxel in Recurrent or Metastatic Head and Neck Carcinoma
NCT00040807Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Nov 2002
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, docetaxel in head and neck carcinoma (HNC), sponsored by Eastern Cooperative Oncology Group. Started Nov 2002; status: completed.
02
Drugs
irinotecandocetaxel
03
Conditions
head and neck carcinoma (HNC)
Beyond the preview
Go deeper on NCT00040807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040807.